Topics

AstraZeneca Starts Artificial Intelligence Collaboration to Accelerate Drug Discovery

06:00 EDT 2 May 2019 | EHEALTHNEWS.EU

AstraZenecaAstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Original Article: AstraZeneca Starts Artificial Intelligence Collaboration to Accelerate Drug Discovery

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca Starts Artificial Intelligence Collaboration to Accelerate Drug Discovery"

Quick Search